Adverse Health Outcomes of Psilocybin, LSD, MDMA, Ibogaine, and 5-MeO-DMT
This cross-sectional study describes health outcomes attributed to recent use of psilocybin, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA), ibogaine, and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a nationally representative survey of US adults.
Authors
- Peter S. Hendricks (ORCID: https://orcid.org/0009-0004-8642-9584)
- Joshua Curtis Black (ORCID: https://orcid.org/0000-0002-7329-2740)
- Karilynn M. Rockhill (ORCID: https://orcid.org/0000-0003-2831-4055)
- Andrew A. Monte (ORCID: https://orcid.org/0000-0002-6210-8418)
- Otto Simonsson (ORCID: https://orcid.org/0000-0003-4197-7566)
- Melissa Bradley
Institutions
- Denver Health Medical Center (US)
- Karolinska Institutet (SE)
- University of Alabama at Birmingham (US)
- University of Colorado Anschutz Medical Campus (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2026-09-29
- DOI
- https://doi.org/10.1001/jamanetworkopen.2026.36756
- Primary Topic
- Psychedelics and Drug Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00